ResearcherFondazione Poliambulanza Istituto OspedalieroNo recent work listed
Francesca Aroldi
Matched on ORCID iD 0000-0002-1202-0258; OpenAlex author ID A5007751483. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 4
2015: 1 paper · 2016: 2 papers · 2017: 1 paper
Papers 4
- Immunotherapy for pancreatic cancer: present and future. Co-author DOI 10.2217/imt-2016-0142↗
- Pancreatic Cancer: Promises and Failures of Target Therapies. Co-author DOI 10.2174/1574887110666150930122720↗
- Pancreatic cancer: New hopes after first line treatment. Co-author DOI 10.4251/wjgo.v8.i9.682↗
- Gemcitabine Plus Nab-Paclitaxel as Second-Line and Beyond Treatment for Metastatic Pancreatic Cancer: a Single Institution Retrospective Analysis. Co-author DOI 10.2174/1574887110666150417115303↗
Closest collaborators
The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Alberto Zaniboni · 4 shared papers, 2015–2017 · strength 0.35
- Edoardo Rosso · 3 shared papers, 2015–2016 · strength 0.20
- Paper Pancreatic Cancer: Promises and Failures of Target Therapies. DOI 10.2174/1574887110666150930122720↗
- Paper Pancreatic cancer: New hopes after first line treatment. DOI 10.4251/wjgo.v8.i9.682↗
- Paper Gemcitabine Plus Nab-Paclitaxel as Second-Line and Beyond Treatment for Metastatic Pancreatic Cancer: a Single Institut… DOI 10.2174/1574887110666150417115303↗
- Paola Bertocchi · 3 shared papers, 2015–2016 · strength 0.20
- Paper Pancreatic Cancer: Promises and Failures of Target Therapies. DOI 10.2174/1574887110666150930122720↗
- Paper Pancreatic cancer: New hopes after first line treatment. DOI 10.4251/wjgo.v8.i9.682↗
- Paper Gemcitabine Plus Nab-Paclitaxel as Second-Line and Beyond Treatment for Metastatic Pancreatic Cancer: a Single Institut… DOI 10.2174/1574887110666150417115303↗
- Giordano Savelli · 2 shared papers, 2015–2016 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.